Jul 14, 2026
Experimental Alzheimer's drug targeting tau protein shows promise in slowing cognitive decline
An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.
8 sources
00